Risk factors
Delcath Systems (DCTH) risk factors
Item 1A of every Delcath Systems, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors59 risks13 new9 dropped12 reworded
Delcath updated its risk factors to reflect financial improvements including a net gain of $2.7 million in 2025. The company added new regulatory risks citing the OBBBA healthcare law enacted on July 4, 2025. Intellectual property, commercialization of HEPZATO, and pricing compliance under Medicaid remain primary focuses.
Filed Feb 26, 2026 - FY2024 10-K risk factors55 risks
Delcath depends heavily on commercializing HEPZATO and CHEMOSAT for treating liver cancer.
Filed Mar 06, 2025